Correction: Loss of  ZNF32  augments the regeneration of nervous lateral line system through negative regulation of  SOX2  transcription

Yuyan Wei; Kai Li; Shaohua Yao; Junping Gao; Jun Li; Yanna Shang; Jie Zhang; Le Zhang; Yanyan Li; Xianming Mo; Wentong Meng; Rong Xiang; Jiankun Hu; Ping Lin; Yuquan Wei

doi:10.18632/oncotarget.27337

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Loss of ZNF32 augments the regeneration of nervous lateral line system through negative regulation of SOX2 transcription

PDF | How to cite

Oncotarget. 2019; 10:7179-7180. https://doi.org/10.18632/oncotarget.27337

Metrics: PDF 1450 views | ?

Yuyan Wei¹, Kai Li¹, Shaohua Yao², Junping Gao¹, Jun Li¹, Yanna Shang³, Jie Zhang¹, Le Zhang¹, Yanyan Li¹, Xianming Mo³, Wentong Meng³, Rong Xiang⁵, Jiankun Hu⁴, Ping Lin¹, Yuquan Wei²

¹ Division of Experimental Oncology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China
² Division of Cancer Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China
³ Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China
⁴ Department of Gastrointestinal Surgery and Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China
⁵ Department of clinical medicine, School of Medicine, Nankai University and Collaborative Innovation Center for Biotherapy, Tianjin, P.R. China

Published: December 24, 2019

This article has been corrected: In Figure 6F, the images of P-1-169 group from Figure 5D were accidentally duplicated. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:70420–70436. DOI: https://doi.org/10.18632/oncotarget.11895.

Figure 6: Identification of NLSs in ZNF32 and the localization of NLS mutants. (A, B) ZNF32 NLS 1 (Aa 170-185). (A) Schematic representation of recombinant, GFP-tagged ZNF32 mutant proteins. Lines represent the deleted sequences in the proteins. (B) The subcellular localization of ZNF32 and NLS 1 mutant proteins. Recombinant proteins are shown in green (GFP), and cell nuclei are shown in blue (DAPI). (C, D) ZNF32 NLS 2 (Aa 186-199). The basic amino acids Lys and Arg were replaced with Ala in NLS 2 mutant. (C) Schematic representation of the recombinant, GFP-tagged ZNF32 mutants. Lines represent the deleted sequences in the proteins. (D) The subcellular localization of ZNF32 and NLS 2 mutant. Recombinant proteins are shown in green (GFP), and cell nuclei are shown in blue (DAPI). (E, F) ZNF32 NLS 3 (Aa 227-239). (E) Schematic representation of the recombinant, GFP-tagged ZNF32 mutants. Lines represent the deleted sequences in the proteins. (F) The subcellular localization of ZNF32 and NLS 3 mutant. Recombinant proteins are shown in green (GFP), and cell nuclei are shown in blue (DAPI). Scale bar = 50 μm.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27337

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: Loss of ZNF32 augments the regeneration of nervous lateral line system through negative regulation of SOX2 transcription